UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8), p.2412-2417

2013

Volltextzugriff (PDF)

MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models

International journal of molecular sciences, 2021-09, Vol.22 (17), p.9168

2021

Volltextzugriff (PDF)

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

Molecular cancer therapeutics, 2010-01, Vol.9 (1), p.145-156

2010

Volltextzugriff (PDF)

Dual IGF-I/II-Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth

Cancer research (Chicago, Ill.), 2011-02, Vol.71 (3), p.1029-1040

2011

Volltextzugriff (PDF)

MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo

Molecular cancer therapeutics, 2012-08, Vol.11 (8), p.1650-1660

2012

Volltextzugriff (PDF)

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

Science translational medicine, 2015-11, Vol.7 (314), p.314ra185

2015

Volltextzugriff (PDF)

Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer

Molecular therapy, 2017-12, Vol.25 (12), p.2705-2714

2017

Volltextzugriff (PDF)

Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126

Clinical cancer research, 2004-06, Vol.10 (11), p.3650-3657

2004

Volltextzugriff (PDF)

Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer

Oncogene, 2018-06, Vol.37 (24), p.3216-3228

2018

Volltextzugriff (PDF)

Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models

Clinical cancer research, 2002-06, Vol.8 (6), p.1974-1983

2002

Volltextzugriff (PDF)

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

Science translational medicine, 2017-06, Vol.9 (394)

2017

Volltextzugriff (PDF)

Sensitization of Tumor-Associated Endothelial Cell Apoptosis by the Novel Vascular-Targeting Agent ZD6126 in Combination with Cisplatin

Clinical cancer research, 2004-11, Vol.10 (22), p.7671-7676

2004

Volltextzugriff (PDF)

The first international conference on vascular targeting: meeting overview

Cancer research (Chicago, Ill.), 2003-03, Vol.63 (5), p.1144

2003

Volltextzugriff (PDF)

Acute Tumor Response to ZD6126 Assessed by Intrinsic Susceptibility Magnetic Resonance Imaging

Neoplasia (New York, N.Y.), 2005-05, Vol.7 (5), p.466-474

2005

Volltextzugriff (PDF)

ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature

Cancer research (Chicago, Ill.), 2002-12, Vol.62 (24), p.7247-7253

2002

Volltextzugriff (PDF)

Single Dose of the Antivascular Agent, ZD6126 (N-Acetylcoichinol-O-Phosphate), Reduces Perfusion for at Least 96 Hours in the GH3 Prolactinoma Rat Tumor Model

Neoplasia (New York, N.Y.), 2004-03, Vol.6 (2), p.150-157

2004

Volltextzugriff (PDF)

Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling

Molecular cancer therapeutics, 2014-02, Vol.13 (2), p.386-398

2014

Volltextzugriff (PDF)

An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding

Molecular cancer therapeutics, 2011-05, Vol.10 (5), p.770-783

2011

Volltextzugriff (PDF)

Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice

Cancer research (Chicago, Ill.), 2002-07, Vol.62 (13), p.3711-3715

2002

Volltextzugriff (PDF)

ZD6126: A novel small molecule vascular targeting agent

International journal of radiation oncology, biology, physics, 2002-12, Vol.54 (5), p.1497-1502

2002

Volltextzugriff (PDF)

Anti-Cancer Drug Discovery and Development Summit

Expert opinion on investigational drugs, 2003-09, Vol.12 (9), p.1577-1582

Blakey, David C

2003

Volltextzugriff (PDF)

DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767

European journal of cancer (1990), 2002-07, Vol.38 (11), p.1543-1552

2002

Volltextzugriff (PDF)

Optimization of Alkylating Agent Prodrugs Derived from Phenol and Aniline Mustards: A New Clinical Candidate Prodrug (ZD2767) for Antibody-Directed Enzyme Prodrug Therapy

Journal of medicinal chemistry, 1995-12, Vol.38 (26), p.5051-5065

1995

Volltextzugriff (PDF)

Abstract 1508: MTL-CEBPA activates the transcription factor CEBPalpha leading to inhibition of hepatocellular cancer growth

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1508-1508

2017

Volltextzugriff (PDF)

1 – 25 von 133

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(124)
Mit Volltextzugriff
(119)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(86)
Life Sciences & Biomedicine
(67)
Humans
(57)
Animals
(37)
Male
(26)
Biological And Medical Sciences
(25)
Female
(25)
Oncology
(24)
Medical Sciences
(23)
Mice
(21)
Antineoplastic Agents
(16)
Pharmacology. Drug Treatments
(16)
Physical Sciences
(15)
Adult
(14)
Middle Aged
(13)
Aged
(11)
Covid-19
(10)
Sars-Cov-2 - Genetics
(10)
Severe Acute Respiratory Syndrome Coronavirus 2
(10)
Covid-19 - Epidemiology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology

MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

Dual IGF-I/II-Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth

MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer

Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126

Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer

Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial

Sensitization of Tumor-Associated Endothelial Cell Apoptosis by the Novel Vascular-Targeting Agent ZD6126 in Combination with Cisplatin

The first international conference on vascular targeting: meeting overview

Acute Tumor Response to ZD6126 Assessed by Intrinsic Susceptibility Magnetic Resonance Imaging

ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature

Single Dose of the Antivascular Agent, ZD6126 (N-Acetylcoichinol-O-Phosphate), Reduces Perfusion for at Least 96 Hours in the GH3 Prolactinoma Rat Tumor Model

Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling

An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding

Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice

ZD6126: A novel small molecule vascular targeting agent

Anti-Cancer Drug Discovery and Development Summit

DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767

Optimization of Alkylating Agent Prodrugs Derived from Phenol and Aniline Mustards: A New Clinical Candidate Prodrug (ZD2767) for Antibody-Directed Enzyme Prodrug Therapy

Abstract 1508: MTL-CEBPA activates the transcription factor CEBPalpha leading to inhibition of hepatocellular cancer growth

Suchergebnisse filtern